← Eichor
Condition: Unresectable Non Small Cell Lung Carcinoma Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Unresectable Non Small Cell Lung Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mut
Phase 3 · 5 location(s) · Astellas Pharma Global Development, Inc. · NCT07566052Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cel
Phase 1/Phase 2 · 40 location(s) · Regeneron Pharmaceuticals · NCT04077099Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 · 39 location(s) · SystImmune Inc. · NCT05983432A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Phase 3 · 45 location(s) · Takeda · NCT07217301Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT05940532A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm
Phase 3 · 237 location(s) · Daiichi Sankyo · NCT06899126Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · 372 location(s) · Pfizer · NCT06758401A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lu
Phase 2 · 43 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT06667908A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With
Phase 2/Phase 3 · 53 location(s) · AbbVie · NCT07005102A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval
Phase 1 · 19 location(s) · AstraZeneca · NCT07391670PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Phase 2 · 11 location(s) · TheraOp · NCT06102057Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
Phase N/A · 4 location(s) · Hedera Dx SA · NCT07096258Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06563999Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Local
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07632365RGL-270 + ICI in Advanced NSCLC
NA · 1 location(s) · Guangdong Association of Clinical Trials · NCT07652125Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Phase 3 · 1 location(s) · Akeso · NCT06617416A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec
Phase 3 · 256 location(s) · Bristol-Myers Squibb · NCT07361497
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.